ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA's mission is to develop and commercialize innovative, safe and effective plasma-derived biologics therapeutics that are highly differentiated and that address unmet medical needs.

ADMA's vision is to become a leading, fully integrated biopharmaceutical company offering a portfolio of therapeutic solutions for patients living with serious, chronic and rare diseases.

ADMA has received several awards, including two awards from the American Association of Patient-Centered Care for its commitment to patient-centered care and an award from the New Jersey Bioscience Council for its excellence in research, education and industrial partnerships.